GlassScriptPhysician profile
Amy Blia Xiong
NPI 1366806473
$778.07
in general payments reported to CMS, 2019-2025
16 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $200 · 2023: $201 · 2024: $222 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $444 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $444.28 |
| Education | $133.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $140.01 | 2024 | Verzenio, Jaypirca |
| Seagen INC. | $118.42 | 2022-2023 | Tukysa |
| Astellas Pharma US INC | $99.99 | 2022 | |
| Novartis Pharmaceuticals Corporation | $74.82 | 2023-2025 | |
| Pfizer INC. | $66.70 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $57.51 | 2023 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $47.22 | 2024-2025 | |
| Novocure INC. | $23.20 | 2025 | Optune Lua (Novottf-200t) |
| Incyte Corporation | $23.14 | 2025 | Monjuvi, Zynyz |
| Genentech USA, INC. | $20.83 | 2023 | Columvi, Polivy, Lunsumio |
| Abbvie INC. | $18.63 | 2023 | |
| Medline Industries LP | $18.61 | 2025 | |
| Rigel Pharmaceuticals, INC. | $17.88 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Tersera Therapeutics LLC | $17.11 | 2023 | Zoladex |
| Eisai INC. | $17.06 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Geron Corporation | $16.94 | 2024 | Rytelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Xiong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.